SCHEMBL18629882

SCHEMBL18629882

CC(=O)c1cc(C)c(O)c(I)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA5A P35218 1/20 0.48
▸ LMNA P02545 2/20 0.45
▸ TTR P02766 2/20 0.42
▸ ESR1 P03372 3/20 0.41
▸ CYP2C19 P33261 1/20 0.39
▸ EYA3 Q99504 1/20 0.39
▸ HSD17B1 P14061 1/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ APP P05067 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ CA1 P00915 1/20 0.37
▸ CA2 P00918 1/20 0.37
▸ TPMT P51580 1/20 0.37
▸ MAPT P10636 1/20 0.36
▸ THRB P10828 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ CTRB1 P17538 1/20 0.36
▸ ALOX12 P18054 1/20 0.36
▸ RECQL P46063 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13624841 0.91 CA5A (0.56) CA5ALMNATTRESR1CYP2C19
SCHEMBL1644952 0.86 CA5A (0.56) CA5ALMNAESR1HSD17B1MEN1
SCHEMBL22991530 0.80 TTR (0.44) LMNATTRESR1CYP2C19EYA3
SCHEMBL13144722 0.80 CA5A (0.50) CA5ALMNAESR1HSD17B1MEN1
SCHEMBL16769478 0.79 CA5A (0.48) CA5ALMNAHSD17B1MEN1KMT2A
SCHEMBL14277282 0.79 CA5A (0.48) CA5ALMNAESR1HSD17B1KMT2A
SCHEMBL6900728 0.78 CA5A (0.48) CA5ALMNAESR1HSD17B1MEN1
SCHEMBL21854475 0.78 KDM4E (0.57) LMNAESR1MEN1KMT2ACA1
SCHEMBL6944075 0.78 LMNA (0.78) CA5ALMNACYP2C19MEN1KMT2A
SCHEMBL2716447 0.77 TTR (0.48) CA5ALMNATTRESR1HSD17B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3348557-B1 IMIDAZO[1,2A]PYRIDINES FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) 2020-04-29 — — EP disclosed
US-10399971-B2 Compound for treating or preventing hyperuricemia or gout JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2019-09-03 — — US disclosed
US-10399971-B2 Compound for treating or preventing hyperuricemia or gout JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2019-09-03 — — US disclosed
US-20180282321-A1 COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2018-10-04 — — US disclosed
EP-3348557-A1 COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd (CN) 2018-07-18 — — EP disclosed
EP-3348557-A1 COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd (CN) 2018-07-18 — — EP disclosed
WO-2017041732-A1 COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT 江苏新元素医药科技有限公司 2017-03-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180282321-A1 COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT SLC10A1, SLC5A1, SLC10A6 CA5A 1148/4885LMNA 2942/4885TTR 1462/4885
US-10399971-B2 Compound for treating or preventing hyperuricemia or gout SLC10A1, SLC5A1, SLC10A6 CA5A 1148/4885LMNA 2942/4885TTR 1462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback